Schedule 13G ownership disclosure

N/A

Security class unavailable · CUSIP: 92539P101

Event date: 2022-12-30

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
859,102
Percent of class
1.3900%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000846087-23-000190
Form type
SC 13G/A
Filer
Verve Therapeutics, Inc.
CIK
CIK 1840574
Filed
Feb 06, 2023
Reporting period
Dec 30, 2022
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub